Evidence map›Paper›PMID 36128406›Full record

ArticleOpen forum infectious diseases2022

Standardization of Epidemiological Surveillance of Group A Streptococcal Cellulitis

Kate M Miller, Theresa Lamagni, Roderick Hay, Jeffrey W Cannon, Michael Marks, Asha C Bowen, David C Kaslow, Thomas Cherian, Anna C Seale, Janessa Pickering and 5 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Serological Responses toOpen forum infectious diseases · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Kate M MillerWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia.ORCID https://orcid.org/0000-0002-1142-7697
Theresa LamagniUK Health Security Agency, London, United Kingdom.ORCID https://orcid.org/0000-0002-3965-8323
Roderick HaySt John's Institute of Dermatology, King's College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-5835-1167
Jeffrey W CannonWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia.
Michael MarksClinical Research Department, Faculty of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0002-7585-4743
Asha C BowenWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia.
David C KaslowPATH, Seattle, Washington, USA.
Thomas CherianMMGH Consulting, Geneva, Switzerland.
Anna C SealeUK Health Security Agency, London, United Kingdom.
Janessa PickeringWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia.
Jessica N DawWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia.
Hannah C MooreWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia.ORCID https://orcid.org/0000-0001-6434-8290
Chris Van BenedenCDC Foundation, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-6250-9238
Jonathan R CarapetisWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia.ORCID https://orcid.org/0000-0002-1182-9792
Laurens ManningWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia.ORCID https://orcid.org/0000-0003-4334-5351
The Kids Research Institute Australia · AUCDC Foundation · USKing's College London · GBProgram for Appropriate Technology in Health · USRoyal London Hospital · GBUK Health Security Agency · GBUniversity of Warwick · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Cellulitis is an acute bacterial infection of the dermis and subcutaneous tissue usually found complicating a wound, ulcer, or dermatosis. This article provides guidelines for the surveillance of cellulitis. The primary objectives of cellulitis surveillance are to (1) monitor trends in rates of infection, (2) describe the demographic and clinical characteristics of patients with cellulitis, (3) estimate the frequency of complications, and (4) describe the risk factors associated with primary and recurrent cellulitis. This article includes case definitions for clinical cellulitis and group A streptococcal cellulitis, based on clinical and laboratory evidence, and case classifications for an initial and recurrent case. It is expected that surveillance for cellulitis will be for all-cause cellulitis, rather than specifically for Strep A cellulitis. Considerations of the type of surveillance are also presented, including identification of data sources and surveillance type. Minimal surveillance necessary for cellulitis is facility-based, passive surveillance. Prospective, active, facility-based surveillance is recommended for estimates of pathogen-specific cellulitis burden. Participant eligibility, surveillance population, and additional surveillance considerations such as active follow-up of cases, the use of International Classification of Disease diagnosis codes, and microbiological sampling of cases are discussed. Finally, the core data elements to be collected on case report forms are presented.

Indexed as

cellulitisepidemiologyinfectious diseaseStreptococcus pyogenessurveillance

Identifiers

PMID36128406
PMCPMC9474943
OpenAlexW4296131457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.